Clinical Trials Browser

Phase 1/2 × INDUSTRY × nirogacestat × Clear all

NCT07150091 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT07150104 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT07084896 2025-07-25

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

Phase 1/2 Active not recruiting

Multiple Myeloma